\-\ Texto\\:\\ \ \(0\)\
\-\ alert\\ and\\ oriented\\ x3\\,\\ communicative\\.\\ no\\ jvd\\.\\ bibasilar\\ crackles\\ in\\ chest\\.\\ tachycardic\\ with\\ irregularly\\ irregular\\ rhythm\\.\\ no\\ rubs\\/murmurs\\.\\ soft\\,\\ nontender\\,\\ normoactive\\ bs\\,\\ no\\ organomegaly\\.\\ pulses\\ 2\\+\\/palpable\\.\\ tender\\ right\\ upper\\ extremity\\ with\\ edema\\ and\\ slight\\ erythema\\.\ \(0\)\
\-\ since\\ the\\ patient\\ was\\ already\\ started\\ on\\ lovenox\\ for\\ thrombotic\\ prophylaxis\\,\\ oral\\ coumadin\\ once\\ a\\ day\\ was\\ added\\ to\\ medication\\ list\\ for\\ 4\\-5\\ days\\ until\\ she\\ reaches\\ therapeutic\\ inr\\ levels\\.\ \(0\)\
\-\ compression\\ ultrasonography\\ with\\ color\\ duplex\\ imaging\\ of\\ right\\ upper\\ extremity\\ showed\\ two\\ brachial\\ veins\\ accompanying\\ the\\ brachial\\ artery\\.\\ at\\ the\\ point\\ of\\ distal\\ brachial\\ artery\\,\\ the\\ right\\ brachial\\ vein\\ is\\ noted\\ to\\ have\\ a\\ lumen\\ with\\ variable\\ echogenicity\\.\\ compression\\ view\\ at\\ the\\ distal\\ brachial\\ veins\\ shows\\ incomplete\\ collapse\\ of\\ the\\ apposing\\ walls\\ of\\ the\\ right\\ brachial\\ vein\\.\\ color\\-flow\\ of\\ the\\ right\\ brachial\\ vein\\ shows\\ a\\ partial\\ filling\\ defect\\ on\\ longitudinal\\ view\\ and\\ non\\-filling\\ color\\ flow\\ on\\ transverse\\ view\\.\\ compression\\ and\\ color\\ flow\\ views\\ of\\ the\\ right\\ internal\\ jugular\\,\\ axillary\\,\\ cephalic\\,\\ basilic\\,\\ and\\ proximal\\ brachial\\ veins\\ showed\\ low\\ echogenicity\\,\\ compressible\\ walls\\,\\ and\\ normal\\ flow\\.\ \(0\)\
\-\ upper\\ extremity\\ dvt\ \(0\)\
\-\ \\*\\ upper\\ extremity\\ dvt\ \(0\)\
\-\ \\*\\ thrombophlebitis\ \(0\)\
\-\ \\*\\ cellulitis\ \(0\)\
\-\ \\*\\ lymphangitis\\,\\ lymph\\ obstruction\\ \ \(0\)\
\-\ \\*\\ venous\\ insufficiency\ \(0\)\
\-\ 82\\ yo\\ female\\ with\\ history\\ significant\\ for\\ htn\\ and\\ hypothyroidism\\ was\\ admitted\\ to\\ wramc\\ for\\ one\\ day\\ of\\ dyspnea\\ associated\\ with\\ exertion\\.\\ it\\ was\\ exacerbated\\ by\\ movement\\ and\\ alleviated\\ with\\ rest\\.\\ patient\\ denied\\ chest\\ pain\\/jaw\\-arm\\ numbness\\/diaphoresis\\/loc\\.\\ she\\ was\\ admitted\\ for\\ atrial\\ fibrillation\\ with\\ right\\ ventricular\\ hypertrophy\\.\\ rate\\ was\\ controlled\\ with\\ metoprolol\\ and\\ iv\\ labetalol\\.\\ she\\ was\\ also\\ given\\ lovenox\\ once\\ daily\\ for\\ thrombotic\\ prophylaxis\\.\\ however\\,\\ during\\ hospital\\ day\\ 5\\,\\ patient\\ was\\ found\\ to\\ have\\ edema\\ in\\ her\\ right\\ upper\\ extremity\\.\ \(0\)\
\-\ this\\ patient\\ had\\ some\\ of\\ the\\ major\\ risk\\ factors\\ that\\ increase\\ the\\ probability\\ of\\ having\\ a\\ dvt\\:\\ she\\ was\\ over\\ the\\ age\\ of\\ 75\\ years\\ and\\ required\\ intravascular\\ access\\ in\\ order\\ to\\ receive\\ a\\ rate\\ controlling\\ medication\\.\\ normally\\,\\ a\\ person\\ with\\ a\\ known\\ reversible\\ cause\\ of\\ dvt\\ can\\ stop\\ coumadin\\ after\\ at\\ least\\ three\\ months\\ of\\ treatment\\.\\ although\\ there\\ was\\ an\\ obvious\\ and\\ reversible\\ cause\\ for\\ her\\ right\\ upper\\ extremity\\ dvt\\,\\ the\\ patient\\ was\\ also\\ newly\\ diagnosed\\ with\\ atrial\\ fibrillation\\.\\ her\\ treatment\\ with\\ coumadin\\ should\\ continue\\ and\\ maintain\\ inr\\ levels\\ between\\ 2\\-3\\ in\\ order\\ to\\ prevent\\ future\\ thrombus\\ formation\\.\\ however\\,\\ if\\ she\\ has\\ an\\ increased\\ risk\\ of\\ falls\\,\\ the\\ risk\\ of\\ suffering\\ a\\ fatal\\ cranial\\ bleed\\ becomes\\ greater\\ than\\ the\\ benefit\\ of\\ preventing\\ an\\ acute\\ thrombotic\\ event\\.\\ in\\ this\\ case\\,\\ removing\\ coumadin\\ after\\ three\\ months\\ of\\ treatment\\ would\\ be\\ reasonable\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ brachial\\:\\ 0\\.39308572988015816\ \(0\)\
\-\ dvt\\:\\ 0\\.23048538945869457\ \(0\)\
\-\ coumadin\\:\\ 0\\.19556506904683818\ \(0\)\
\-\ extremity\\:\\ 0\\.18980288696736553\ \(0\)\
\-\ was\\:\\ 0\\.1683748872413461\ \(0\)\
\-\ thrombotic\\:\\ 0\\.15996384345306666\ \(0\)\
\-\ color\\:\\ 0\\.15838904061113568\ \(0\)\
\-\ upper\\:\\ 0\\.1408233354301616\ \(0\)\
\-\ of\\:\\ 0\\.13752146757181619\ \(0\)\
\-\ the\\:\\ 0\\.13145664507504554\ \(0\)\
\-\ right\\:\\ 0\\.13105384205522677\ \(0\)\
\-\ she\\:\\ 0\\.13072480966718913\ \(0\)\
\-\ flow\\:\\ 0\\.11701723674454573\ \(0\)\
\-\ veins\\:\\ 0\\.1169263152491077\ \(0\)\
\-\ lovenox\\:\\ 0\\.1094501304693438\ \(0\)\
\-\ and\\:\\ 0\\.10890816430198248\ \(0\)\
\-\ with\\:\\ 0\\.10320272746194059\ \(0\)\
\-\ reversible\\:\\ 0\\.10158393085178005\ \(0\)\
\-\ fibrillation\\:\\ 0\\.09827143247003954\ \(0\)\
\-\ prophylaxis\\:\\ 0\\.09684897646610863\ \(0\)\
\-\ compression\\:\\ 0\\.09648959376392681\ \(0\)\
\-\ view\\:\\ 0\\.09648959376392681\ \(0\)\
\-\ vein\\:\\ 0\\.09444553747760817\ \(0\)\
\-\ risk\\:\\ 0\\.09414652375151769\ \(0\)\
\-\ inr\\:\\ 0\\.09396610745511336\ \(0\)\
\-\ for\\:\\ 0\\.09318424532576355\ \(0\)\
\-\ echogenicity\\:\\ 0\\.08572882983715886\ \(0\)\
\-\ day\\:\\ 0\\.08393024752216961\ \(0\)\
\-\ once\\:\\ 0\\.08255891573199411\ \(0\)\
\-\ atrial\\:\\ 0\\.08255891573199411\ \(0\)\
\-\ walls\\:\\ 0\\.08238089072205115\ \(0\)\
\-\ her\\:\\ 0\\.08231753474810731\ \(0\)\
\-\ medication\\:\\ 0\\.08118921411967495\ \(0\)\
\-\ order\\:\\ 0\\.08118921411967495\ \(0\)\
\-\ admitted\\:\\ 0\\.07197493824147969\ \(0\)\
\-\ patient\\:\\ 0\\.07142603688140658\ \(0\)\
\-\ communicative\\:\\ 0\\.07023880283143581\ \(0\)\
\-\ basilic\\:\\ 0\\.07023880283143581\ \(0\)\
\-\ lymphangitis\\:\\ 0\\.07023880283143581\ \(0\)\
\-\ levels\\:\\ 0\\.0696398155878833\ \(0\)\
\-\ filling\\:\\ 0\\.06802510999764935\ \(0\)\
\-\ apposing\\:\\ 0\\.06711692588366058\ \(0\)\
\-\ labetalol\\:\\ 0\\.06711692588366058\ \(0\)\
\-\ rate\\:\\ 0\\.06656376504566683\ \(0\)\
\-\ to\\:\\ 0\\.06588057172243682\ \(0\)\
\-\ treatment\\:\\ 0\\.06276531725249827\ \(0\)\
\-\ removing\\:\\ 0\\.061780041991229016\ \(0\)\
\-\ cause\\:\\ 0\\.059841678549948686\ \(0\)\
\-\ three\\:\\ 0\\.05896604780302018\ \(0\)\
\-\ alleviated\\:\\ 0\\.05865816504345379\ \(0\)\
\-\ metoprolol\\:\\ 0\\.05865816504345379\ \(0\)\
\-\ showed\\:\\ 0\\.058508618372272864\ \(0\)\
\-\ controlling\\:\\ 0\\.05784694218244713\ \(0\)\
\-\ compressible\\:\\ 0\\.057113101841393524\ \(0\)\
\-\ wramc\\:\\ 0\\.05644315809879745\ \(0\)\
\-\ reaches\\:\\ 0\\.055826869597206175\ \(0\)\
\-\ cephalic\\:\\ 0\\.055826869597206175\ \(0\)\
\-\ suffering\\:\\ 0\\.055826869597206175\ \(0\)\
\-\ x3\\:\\ 0\\.0547250652346719\ \(0\)\
\-\ in\\:\\ 0\\.05463025640405195\ \(0\)\
\-\ artery\\:\\ 0\\.054555391542718996\ \(0\)\
\-\ normoactive\\:\\ 0\\.05332128115102222\ \(0\)\
\-\ added\\:\\ 0\\.05332128115102222\ \(0\)\
\-\ probability\\:\\ 0\\.05332128115102222\ \(0\)\
\-\ edema\\:\\ 0\\.052390571230730584\ \(0\)\
\-\ jvd\\:\\ 0\\.05213439861979288\ \(0\)\
\-\ preventing\\:\\ 0\\.05213439861979288\ \(0\)\
\-\ however\\:\\ 0\\.05199186955857402\ \(0\)\
\-\ intravascular\\:\\ 0\\.05177621794896196\ \(0\)\
\-\ shows\\:\\ 0\\.05155533347087928\ \(0\)\
\-\ thrombophlebitis\\:\\ 0\\.05143396178417048\ \(0\)\
\-\ fatal\\:\\ 0\\.05143396178417048\ \(0\)\
\-\ months\\:\\ 0\\.051130832082933224\ \(0\)\
\-\ duplex\\:\\ 0\\.05110627420636588\ \(0\)\
\-\ stop\\:\\ 0\\.05110627420636588\ \(0\)\
\-\ distal\\:\\ 0\\.051038066791247345\ \(0\)\
\-\ newly\\:\\ 0\\.050791965425890026\ \(0\)\
\-\ reasonable\\:\\ 0\\.050791965425890026\ \(0\)\
\-\ an\\:\\ 0\\.050385414854796175\ \(0\)\
\-\ ultrasonography\\:\\ 0\\.050199404203247\ \(0\)\
\-\ exacerbated\\:\\ 0\\.050199404203247\ \(0\)\
\-\ tachycardic\\:\\ 0\\.049919391675136544\ \(0\)\
\-\ at\\:\\ 0\\.04976824297058081\ \(0\)\
\-\ bibasilar\\:\\ 0\\.049649206201232365\ \(0\)\
\-\ irregularly\\:\\ 0\\.049649206201232365\ \(0\)\
\-\ person\\:\\ 0\\.049649206201232365\ \(0\)\
\-\ organomegaly\\:\\ 0\\.049388181342240337\ \(0\)\
\-\ access\\:\\ 0\\.04913571623501977\ \(0\)\
\-\ accompanying\\:\\ 0\\.048891267261709545\ \(0\)\
\-\ list\\:\\ 0\\.04865434100118673\ \(0\)\
\-\ falls\\:\\ 0\\.04865434100118673\ \(0\)\
\-\ maintain\\:\\ 0\\.04777343896846883\ \(0\)\
\-\ already\\:\\ 0\\.046616341758428624\ \(0\)\
\-\ benefit\\:\\ 0\\.046616341758428624\ \(0\)\
\-\ chest\\:\\ 0\\.04636716990530251\ \(0\)\
\-\ receive\\:\\ 0\\.04626630439446511\ \(0\)\
\-\ cellulitis\\:\\ 0\\.04609707789173891\ \(0\)\
\-\ exertion\\:\\ 0\\.04609707789173891\ \(0\)\
\-\ hypothyroidism\\:\\ 0\\.045769390313934316\ \(0\)\
\-\ controlled\\:\\ 0\\.045769390313934316\ \(0\)\
\-\ bs\\:\\ 0\\.04545508153345845\ \(0\)\
\-\ crackles\\:\\ 0\\.045302611285279085\ \(0\)\
\-\ jugular\\:\\ 0\\.045302611285279085\ \(0\)\
\-\ bleed\\:\\ 0\\.04500644031277974\ \(0\)\
\-\ 82\\:\\ 0\\.044721241192404844\ \(0\)\
\-\ therapeutic\\:\\ 0\\.04444622996094664\ \(0\)\
\-\ future\\:\\ 0\\.04405129744980877\ \(0\)\
\-\ have\\:\\ 0\\.04388162375785586\ \(0\)\
\-\ htn\\:\\ 0\\.043798832342588204\ \(0\)\
\-\ event\\:\\ 0\\.043798832342588204\ \(0\)\
\-\ axillary\\:\\ 0\\.04320167303326005\ \(0\)\
\-\ incomplete\\:\\ 0\\.04308760434062275\ \(0\)\
\-\ continue\\:\\ 0\\.04308760434062275\ \(0\)\
\-\ no\\:\\ 0\\.04284756123615135\ \(0\)\
\-\ variable\\:\\ 0\\.042647513366159094\ \(0\)\
\-\ after\\:\\ 0\\.042613328578378996\ \(0\)\
\-\ insufficiency\\:\\ 0\\.04233320458568322\ \(0\)\
\-\ becomes\\:\\ 0\\.04203122486456782\ \(0\)\
\-\ longitudinal\\:\\ 0\\.0417406433630402\ \(0\)\
\-\ rhythm\\:\\ 0\\.04164616983512511\ \(0\)\
\-\ pulses\\:\\ 0\\.04164616983512511\ \(0\)\
\-\ daily\\:\\ 0\\.04164616983512511\ \(0\)\
\-\ nontender\\:\\ 0\\.0413695114764972\ \(0\)\
\-\ hypertrophy\\:\\ 0\\.0413695114764972\ \(0\)\
\-\ also\\:\\ 0\\.04131810177371089\ \(0\)\
\-\ collapse\\:\\ 0\\.04119044536102558\ \(0\)\
\-\ obvious\\:\\ 0\\.040844342333338474\ \(0\)\
\-\ thrombus\\:\\ 0\\.040844342333338474\ \(0\)\
\-\ least\\:\\ 0\\.04059460705983747\ \(0\)\
\-\ alert\\:\\ 0\\.040432506421502756\ \(0\)\
\-\ movement\\:\\ 0\\.040432506421502756\ \(0\)\
\-\ prevent\\:\\ 0\\.0402737483037004\ \(0\)\
\-\ normally\\:\\ 0\\.04004158510916643\ \(0\)\
\-\ on\\:\\ 0\\.039794439637127026\ \(0\)\
\-\ erythema\\:\\ 0\\.0397425379708042\ \(0\)\
\-\ denied\\:\\ 0\\.039669556420348175\ \(0\)\
\-\ oriented\\:\\ 0\\.03959726015278392\ \(0\)\
\-\ lumen\\:\\ 0\\.03910934606851507\ \(0\)\
\-\ dyspnea\\:\\ 0\\.03865051695891967\ \(0\)\
\-\ 75\\:\\ 0\\.03852429288734988\ \(0\)\
\-\ slight\\:\\ 0\\.03846194845015664\ \(0\)\
\-\ major\\:\\ 0\\.038400104776901346\ \(0\)\
\-\ rest\\:\\ 0\\.037980573216323595\ \(0\)\
\-\ having\\:\\ 0\\.03786478914082849\ \(0\)\
\-\ factors\\:\\ 0\\.037151871355925174\ \(0\)\
\-\ started\\:\\ 0\\.03699632069325166\ \(0\)\
\-\ ventricular\\:\\ 0\\.03694516106366306\ \(0\)\
\-\ until\\:\\ 0\\.036547679472572946\ \(0\)\
\-\ point\\:\\ 0\\.036309285942693545\ \(0\)\
\-\ cranial\\:\\ 0\\.0358979390895759\ \(0\)\
\-\ increase\\:\\ 0\\.03525772316740591\ \(0\)\
\-\ oral\\:\\ 0\\.03517624625973319\ \(0\)\
\-\ formation\\:\\ 0\\.03481990779394165\ \(0\)\
\-\ views\\:\\ 0\\.034666678937364664\ \(0\)\
\-\ lymph\\:\\ 0\\.03415318897115206\ \(0\)\
\-\ irregular\\:\\ 0\\.03390873999784184\ \(0\)\
\-\ partial\\:\\ 0\\.033840299583421565\ \(0\)\
\-\ transverse\\:\\ 0\\.033840299583421565\ \(0\)\
\-\ hospital\\:\\ 0\\.03244219568883467\ \(0\)\
\-\ greater\\:\\ 0\\.0323574297399213\ \(0\)\
\-\ defect\\:\\ 0\\.03221819455460618\ \(0\)\
\-\ tender\\:\\ 0\\.03210859133833791\ \(0\)\
\-\ since\\:\\ 0\\.03181498746349361\ \(0\)\
\-\ diagnosed\\:\\ 0\\.03181498746349361\ \(0\)\
\-\ iv\\:\\ 0\\.03138217458383923\ \(0\)\
\-\ venous\\:\\ 0\\.031357457079704686\ \(0\)\
\-\ required\\:\\ 0\\.031357457079704686\ \(0\)\
\-\ would\\:\\ 0\\.031090676202771932\ \(0\)\
\-\ obstruction\\:\\ 0\\.03076398191606404\ \(0\)\
\-\ given\\:\\ 0\\.030212996120942318\ \(0\)\
\-\ this\\:\\ 0\\.03018390496874004\ \(0\)\
\-\ although\\:\\ 0\\.029900389074571168\ \(0\)\
\-\ internal\\:\\ 0\\.02959998051883727\ \(0\)\
\-\ should\\:\\ 0\\.028658271108195937\ \(0\)\
\-\ between\\:\\ 0\\.028537559853044868\ \(0\)\
\-\ known\\:\\ 0\\.028435578283651935\ \(0\)\
\-\ found\\:\\ 0\\.02841871191124374\ \(0\)\
\-\ during\\:\\ 0\\.027819289782060663\ \(0\)\
\-\ days\\:\\ 0\\.02780371951199126\ \(0\)\
\-\ some\\:\\ 0\\.027634493009265057\ \(0\)\
\-\ age\\:\\ 0\\.027573866743858835\ \(0\)\
\-\ proximal\\:\\ 0\\.027439178249369103\ \(0\)\
\-\ yo\\:\\ 0\\.027439178249369103\ \(0\)\
\-\ years\\:\\ 0\\.026922817479273352\ \(0\)\
\-\ two\\:\\ 0\\.02608251636871802\ \(0\)\
\-\ if\\:\\ 0\\.025519033395623673\ \(0\)\
\-\ significant\\:\\ 0\\.025358859799202497\ \(0\)\
\-\ low\\:\\ 0\\.025201950521828154\ \(0\)\
\-\ one\\:\\ 0\\.025146677521171654\ \(0\)\
\-\ than\\:\\ 0\\.024897410986007916\ \(0\)\
\-\ over\\:\\ 0\\.024421854744208053\ \(0\)\
\-\ acute\\:\\ 0\\.023759433714399383\ \(0\)\
\-\ increased\\:\\ 0\\.023750240285336482\ \(0\)\
\-\ soft\\:\\ 0\\.023382460024901318\ \(0\)\
\-\ noted\\:\\ 0\\.02328670474304196\ \(0\)\
\-\ associated\\:\\ 0\\.023149516331024692\ \(0\)\
\-\ imaging\\:\\ 0\\.023081828018812173\ \(0\)\
\-\ can\\:\\ 0\\.02304820571243393\ \(0\)\
\-\ it\\:\\ 0\\.022482405889629097\ \(0\)\
\-\ case\\:\\ 0\\.02206529526639614\ \(0\)\
\-\ had\\:\\ 0\\.02188292065939228\ \(0\)\
\-\ female\\:\\ 0\\.02119377616887702\ \(0\)\
\-\ has\\:\\ 0\\.020061708004876028\ \(0\)\
\-\ that\\:\\ 0\\.019059948093563147\ \(0\)\
\-\ by\\:\\ 0\\.018651287650240142\ \(0\)\
\-\ normal\\:\\ 0\\.017932538024216984\ \(0\)\
\-\ be\\:\\ 0\\.01781688278146971\ \(0\)\
\-\ there\\:\\ 0\\.017475920665144713\ \(0\)\
\-\ history\\:\\ 0\\.01678026002730642\ \(0\)\
\-\ is\\:\\ 0\\.012027989279187891\ \(0\)\
